Survival-apoptosis associated signaling in GNE myopathy-cultured myoblasts

References

• Argov Z, Mitrani-Rosenbaum S. The hereditary inclusion body myopathy enigma and its future therapy. Neurotherapeutics 2008;5:633–7
   PubMed Web of Science ®Google Scholar
• Sela I, Milman Krentsis I, Shlomai Z, et al. The proteomic profile of hereditary inclusion body myopathy. PLoS One 2011;6:e16334
   PubMed Web of Science ®Google Scholar
• Milman KI, Sela I, Eiges R, et al. GNE is involved in the early development of skeletal and cardiac muscle. PLoS One 2011;6:e21389
   PubMedGoogle Scholar
• Sela I, Yakovlev L, Becker-Cohen M, et al. Variable phenotypes of knockin mice carrying the M712T GNE mutation. Neuromolecular Med 2013;15:180–91
   PubMed Web of Science ®Google Scholar
• Amsili S, Shlomai Z, Levitzki R, et al. Characterization of hereditary inclusion body myopathy myoblasts: possible primary impairment of apoptotic events. Cell Death Differ 2007;14:1916–24
   PubMed Web of Science ®Google Scholar
• Eisenberg I, Novershtern N, Itzhaki Z, et al. Mitochondrial processes are impaired in hereditary inclusion body myopathy. Hum Mol Genet 2008;17:3663–74
   PubMed Web of Science ®Google Scholar
• Glass DJ, Campbell KP, Rudnicki MA. Welcome to skeletal muscle. Skelet Muscle 2011;1:1
   Google Scholar
• Frost RA, Lang CH. Protein kinase B/Akt: a nexus of growth factor and cytokine signaling in determining muscle mass. Appl Physiol 2007;103:378–87
   PubMed Web of Science ®Google Scholar
• Glass DJ. PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. Curr Top Microbiol Immunol 2010;346:267–78
   PubMed Web of Science ®Google Scholar
• Bayascas JR. PDK1: the major transducer of PI 3-kinase actions. Curr Top Microbiol Immunol 2010;346:9–29
   PubMed Web of Science ®Google Scholar
• Wijesekara N, Konrad D, Eweida M, et al. Muscle-specific PTEN deletion protects against insulin resistance and diabetes. Mol Cell Biol 2005;l25:1135–45
   Google Scholar
• Hu Z, Wang H, Lee IH, et al. PTEN inhibition improves muscle regeneration in mice fed a high fat diet. Diabetes 2010;59:1312–20
   PubMed Web of Science ®Google Scholar
• Cohen P, Alessi DR, Cross DA. PDK1, one of the missing links in insulin signal? FEBS Lett 1997;410:3–10
   PubMed Web of Science ®Google Scholar
• Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261–74
   PubMed Web of Science ®Google Scholar
• Forde JE, Dale TC. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci 2007;64:1930–44
   PubMed Web of Science ®Google Scholar
• Ciaraldi TP, Nikoulina SE, Bandukwala RA, et al. Role of glycogen synthase kinase-3 alpha in insulin action in cultured human skeletal muscle cells. Endocrinology 2007;148:4393–9
   PubMed Web of Science ®Google Scholar
• Ciaraldi TP, Carter L, Mudaliar S, Henry RR. GSK-3beta and control of glucose metabolism and insulin action in human skeletal muscle. Mol Cell Endocrinol 2010;315:153–8
   PubMed Web of Science ®Google Scholar
• Takahashi-Yanaga F, Sasaguri T. GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy. Cell Signal 2008;20:581–9
   PubMed Web of Science ®Google Scholar
• Bois PR, Grosveld GC. FKHR (FOXO1a) is required for myotube fusion of primary mouse myoblasts. EMBO J 2003;22:1147–57
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Kamei Y, Sugita S, et al. The cathepsin L gene is a direct target of FOXO1 in skeletal muscle. Biochem J 2010;427:171–8
   PubMed Web of Science ®Google Scholar
• Wan M, Wu X, Guan KL, et al. Muscle atrophy in transgenic mice expressing a human TSC1 transgene. FEBS Lett 2006;580:5621–7
   PubMed Web of Science ®Google Scholar
• Sandri M, Carraro U. Apoptosis of skeletal muscles during development and disease. Int Biochem Cell Biol 1999;31:1373–90
   PubMed Web of Science ®Google Scholar
• Schwartz LM, Gao Z, Brown C, et al. Cell death in myoblasts and muscles. Methods Mol Biol 2009;559:313–32
   PubMedGoogle Scholar
• He C, Bassik MC, Moresi V, et al. Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. Nature 2012;481:511–15
   PubMed Web of Science ®Google Scholar
• Asselin E, Mills GB, Tsang BK. XIAP regulates AKT activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Cancer Res 2001;61:1862–8
   PubMed Web of Science ®Google Scholar
• Wang JH, Zhou YJ, Bai X, He P. Jolkinolide B from Euphorbia fischeriana Steud induces apoptosis in human leukemic U937 cells through PI3K/Akt and XIAP pathways. Mol Cells 2011;32:451–7
   PubMed Web of Science ®Google Scholar
• Pramanik KC, Kudugunti SK, Fofaria NM, et al. Caffeic acid phenethyl ester (CAPE) suppresses melanoma tumor growth by inhibiting PI3K/AKT/XIAP pathway. Carcinogenesis 2013;34:2061–70
   PubMed Web of Science ®Google Scholar
• Elhasid R, Larisch S. ARTS-based anticancer therapy: taking aim at cancer stem cells. Future Oncol 2011;7:1185–94
   PubMed Web of Science ®Google Scholar
• Kuzman JA, Gerdes AM, Kobayashi S, Liang Q. Thyroid hormone activates Akt and prevents serum starvation-induced cell death in neonatal rat cardiomyocytes. J Mol Cell Cardiol 2005;39:841–4
   PubMed Web of Science ®Google Scholar
• Mofarrahi M, Guo Y, Haspel JA, et al. Autophagic flux and oxidative capacity of skeletal muscles during acute starvation. Autophagy 2013;9:1604–20
   PubMed Web of Science ®Google Scholar
• Prats C, Gómez-Cabello A, Hansen AV. Intracellular compartmentalization of skeletal muscle glycogen metabolism and insulin signaling. Exp Physiol 2011;96:385–90
   PubMed Web of Science ®Google Scholar
• Bonetto A, Aydogdu T, Jin X, et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab 2012;303:E410–21
   PubMed Web of Science ®Google Scholar
• Di R, Wu X, Chang Z, et al. S6K inhibition renders cardiac protection against myocardial infarction through PDK1 phosphorylation of Akt. Biochem J 2012;441:199–207
   PubMed Web of Science ®Google Scholar
• Rahmani A, Alzohairy M, Babiker AY, et al. Clinicopathological significance of PTEN andBCL2 expressions in oral squamous cell carcinoma. Int J Clin Exp Pathol 2012;5:965–71
   PubMed Web of Science ®Google Scholar
• van der Velden JL, Langen RC, Kelders MC, et al. Inhibition of glycogen synthase kinase-3beta activity is sufficient to stimulate myogenic differentiation. Am J Physiol Cell Physiol 2006;290:C453–62
   PubMed Web of Science ®Google Scholar
• Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signaling. Biochem J 1998;333:471–90
   PubMed Web of Science ®Google Scholar
• Shepherd PR. Mechanisms regulating phosphoinositide 3-kinase signalling in insulin-sensitive tissues. Acta Physiol Scand 2005;183:3–12
   PubMedGoogle Scholar
• Levitzki A, Klein S. Signal transduction therapy of cancer. Mol Aspects Med 2010;31:287–329
   PubMed Web of Science ®Google Scholar
• Klein S, Levitzki A. Targeting the EGFR and the PKB pathway in cancer. Curr Opin Cell Biol 2009;21:185–93
   PubMed Web of Science ®Google Scholar
• Levitzki A. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu Rev Pharmacol Toxicol 2013;53:161–85
   PubMed Web of Science ®Google Scholar
• Shushan A, Rojansky N, Laufer N, et al. The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth. Hum Reprod 2004;19:1957–67
   PubMed Web of Science ®Google Scholar
• Shushan A, Ben-Bassat H, Mishani E, et al. Inhibition of leiomyoma cell proliferation in vitro by genistein and the protein tyrosine kinase inhibitor TKS050. Fertil Steril 2007;87:127–35
   PubMed Web of Science ®Google Scholar
• Ben-Bassat H. Biological activity of tyrosine kinase inhibitors: novel agents for psoriasis therapy. Curr Opin Investig Drugs 2001;2:1539–45 (Review)
   PubMedGoogle Scholar